Evidence map›Paper›PMID 27219338›Full record

ArticleVaccine2016

Antigenic characterization of influenza viruses produced using synthetic DNA and novel backbones.

Pirada Suphaphiphat, Lynne Whittaker, Ivna De Souza, Rodney S Daniels, Philip R Dormitzer, John W McCauley, Ethan C Settembre

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Pirada SuphaphiphatSeqirus (previously Novartis Influenza Vaccines), 45 Sidney Street, Cambridge, MA 02139, USA. Electronic address: Pirada.Suphaphiphat@seqirus.com.
Lynne WhittakerCrick Worldwide Influenza Centre, The Francis Crick Institute, Mill Hill Laboratory, The Ridgeway, Mill Hill, London NW7 1AA, UK.
Ivna De SouzaSeqirus (previously Novartis Influenza Vaccines), 45 Sidney Street, Cambridge, MA 02139, USA.
Rodney S DanielsCrick Worldwide Influenza Centre, The Francis Crick Institute, Mill Hill Laboratory, The Ridgeway, Mill Hill, London NW7 1AA, UK.
Philip R DormitzerSeqirus (previously Novartis Influenza Vaccines), 45 Sidney Street, Cambridge, MA 02139, USA.
John W McCauleyCrick Worldwide Influenza Centre, The Francis Crick Institute, Mill Hill Laboratory, The Ridgeway, Mill Hill, London NW7 1AA, UK.
Ethan C SettembreSeqirus (previously Novartis Influenza Vaccines), 45 Sidney Street, Cambridge, MA 02139, USA.
Seqirus (United States) · USThe Francis Crick Institute · GB

Funding

Medical Research Council MC_U117512723
6 · The paper itself

Abstract

The global system for manufacturing seasonal influenza vaccines has been developed to respond to the natural evolution of influenza viruses, but the problem of antigenic mismatch continues to be a challenge in certain years. In some years, mismatches arise naturally due to the antigenic drift of circulating viruses after vaccine strain selection has already been made. In other years, antigenic differences between the vaccine virus and circulating viruses are introduced as part of the current system, which relies on the use of egg-adapted isolates as a starting material for candidate vaccine viruses (CVVs). Improving the current process for making vaccine viruses can provide great value. We have previously established a synthetic approach for rapidly generating influenza viruses in a vaccine-approved Madin Darby canine kidney (MDCK) cell line using novel, high-growth backbones that increase virus rescue efficiency and antigen yield. This technology also has the potential to produce viruses that maintain antigenic similarity to the intended reference viruses, depending on the hemagglutinin (HA) and neuraminidase (NA) sequences used for gene synthesis. To demonstrate this utility, we generated a panel of synthetic viruses using HA and NA sequences from recent isolates and showed by hemagglutination inhibition (HI) tests that all synthetic viruses were antigenically-like their conventional egg- or cell-propagated reference strains and there was no impact of the novel backbones on antigenicity. This synthetic approach can be used for the efficient production of CVVs that may be more representative of circulating viruses and may be used for both egg- and cell-based vaccine manufacturing platforms. When combined with mammalian cell culture technology for antigen production, synthetic viruses generated using HA and NA sequences from a non-egg-adapted prototype can help to reduce the potential impact of antigenic differences between vaccine virus and circulating viruses on vaccine effectiveness.

Indexed as

Virus CultivationAnimalsAntigens, ViralDNADogsFerretsHemagglutination Inhibition TestsHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesMadin Darby Canine Kidney CellsNeuraminidaseOrthomyxoviridaeReassortant VirusesReverse GeneticsVaccines, SyntheticAntigens, ViralDNAHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesNeuraminidaseVaccines, SyntheticAntigenicityHemagglutination inhibitionSynthetic influenza virus

Identifiers

PMID27219338
PMCPMC4940205
OpenAlexW2394995010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.